药品审批更新。
Pharmaceutical approval update.
作者信息
Goldenberg Marvin M
出版信息
P T. 2014 May;39(5):337-44.
Abstract
Droxidopa (Northera) for neurogenic orthostatic hypotension, elosulfase alfa (Vimizim) for Morquio A syndrome, and sodium hyaluronate in phosphate-buffered saline (Monovisc) to address knee osteoarthritis.
摘要
用于神经源性直立性低血压的屈昔多巴（诺特罗）、用于莫尔基奥A综合征的艾洛硫酸酯酶α（维米齐姆）以及用于治疗膝关节骨关节炎的磷酸盐缓冲盐水中的透明质酸钠（莫诺维茨）。
相似文献
1
Pharmaceutical approval update.
P T. 2014 May;39(5):337-44.
2
Long-term Immunogenicity of Elosulfase Alfa in the Treatment of Morquio A Syndrome: Results From MOR-005, a Phase III Extension Study.
Clin Ther. 2017 Jan;39(1):118-129.e3. doi: 10.1016/j.clinthera.2016.11.017. Epub 2016 Dec 10.
3
Droxidopa (Northera) for neurogenic orthostatic hypotension.
Med Lett Drugs Ther. 2015 Jun 22;57(1471):92-3.
4
Elosulfase alfa: first global approval.
Drugs. 2014 Apr;74(6):713-8. doi: 10.1007/s40265-014-0210-z.
5
Safety, immunogenicity, and clinical outcomes in patients with Morquio A syndrome participating in 2 sequential open-label studies of elosulfase alfa enzyme replacement therapy (MOR-002/MOR-100), representing 5 years of treatment.
Mol Genet Metab. 2018 Apr;123(4):479-487. doi: 10.1016/j.ymgme.2018.02.011. Epub 2018 Feb 19.
6
Elosulfase Alfa: a review of its use in patients with mucopolysaccharidosis type IVA (Morquio A syndrome).
BioDrugs. 2014 Oct;28(5):465-75. doi: 10.1007/s40259-014-0108-z.
7
Immunogenicity of Elosulfase Alfa, an Enzyme Replacement Therapy in Patients With Morquio A Syndrome: Results From MOR-004, a Phase III Trial.
Clin Ther. 2015 May 1;37(5):1012-1021.e6. doi: 10.1016/j.clinthera.2014.11.005. Epub 2014 Dec 6.
8
Persistent unexplained chest pain and dyspnea in a patient with coronary artery disease: a case report.
BMC Cardiovasc Disord. 2020 Feb 4;20(1):54. doi: 10.1186/s12872-020-01348-w.
9
Droxidopa as an effective treatment for refractory neurogenic orthostatic hypotension and reflex bradycardia in amyloid light-chain amyloidosis: a case report.
J Med Case Rep. 2020 Jun 20;14(1):73. doi: 10.1186/s13256-020-02405-w.
10
Meta-analysis of the safety and efficacy of droxidopa for neurogenic orthostatic hypotension.
Clin Auton Res. 2016 Jun;26(3):171-80. doi: 10.1007/s10286-016-0349-7. Epub 2016 Mar 7.
引用本文的文献
1
Clinical Utility of Elosulfase Alfa in the Treatment of Morquio A Syndrome.
Drug Des Devel Ther. 2022 Jan 10;16:143-154. doi: 10.2147/DDDT.S219433. eCollection 2022.
2
Computational Drug Repurposing Algorithm Targeting TRPA1 Calcium Channel as a Potential Therapeutic Solution for Multiple Sclerosis.
Pharmaceutics. 2019 Sep 2;11(9):446. doi: 10.3390/pharmaceutics11090446.
3
Therapeutic efficacy of three hyaluronic acid formulations in young and middle-aged patients with early-stage meniscal injuries.
J Phys Ther Sci. 2017 Jul;29(7):1148-1153. doi: 10.1589/jpts.29.1148. Epub 2017 Jul 15.
4
Role of elosulfase alfa in mucopolysaccharidosis IVA.
Appl Clin Genet. 2016 Jun 14;9:67-74. doi: 10.2147/TACG.S69080. eCollection 2016.
5
Efficacy of atomoxetine versus midodrine for the treatment of orthostatic hypotension in autonomic failure.
Hypertension. 2014 Dec;64(6):1235-40. doi: 10.1161/HYPERTENSIONAHA.114.04225. Epub 2014 Sep 2.
Zotero 插件